-
Posted by
Two Blokes Jun 10 -
Filed in
Stock
-
7 views
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, for a novel, long-acting biopharmaceutical product.
